مطالعات کلینیکی

همکاری با ما

 شرکت ژن تکنولوژی گسترش سلول های بنیادی مزانشیمال خود را گسترش داده است تا بتواند انواع سلولهای بنیادی و محصولات  بیولوژیک قابل استفاده، موثر و استاندارد بدون نیاز به تطبیق ژنتیکی در جهان، تولید کند. همه محصولات ما باید مورد تایید استانداردهای دقیق و جدید قرار بگیرند.

اطلاعات بیشتر

برای کسب اطلاعات بیشتر با شرکت سل ژن تماس بگیرید

همانطور که شرکت سل ژن به سوی  سوی آینده گام بر می دارد ، ما باید استفاده از محصولات مان را برای مداوای شرایط صعب العلاج مانند ARDS ناشی از کووید ۱۹ ، زخم های سوختگی و دیابتی ، فیستول کرون ، بیماری التهابی روده ، سکته مغزی و ‌قلبی ، آسیبهای نخاعی و بقیه موارد مورد نیاز پزشکی در نظر بگیریم.

As our company moves forward, we will consider our products usage for incurable conditions such as ARDS due to COVID-19, burn & diabetic wound, Crohn’s fistula, IBD, stroke, myocardial infarction, spinal cord injury and other unmet medical needs.
Indication
Product Candidate
preclinical
Phase I
Phase II
Phase III
Approval
ARDS due to COVID-19
CytoStem hUC
Burn Wound
CytoStem hAD
Diabetic Wound
CytoStem hAD CytoStem hUD
Bone Defect Regeneration
CytoStem hAD CytoStem hUD
Skin Substitute
CytoStem hAD CytoStem hUD
Osteoarthritis
CytoStem hAD
Crohn’s Fistula
CytoStem hAD
IBD
CytoStem hAD
Scroll to Top

Hi
Here you can see some frequently asked questions or contact us!

What passage are your cells?

Our human mesenchymal stem/stromal cells (hMSCs) are provided at a population doubling level (PDL) of 8-10 post-mononuclear isolation (Bone Marrow; Equivalent Passage 2) or 14-18 post-isolation from the perivascular region of Wharton’s Jelly (Umbilical Cord; Equivalent Passage 3). Due to variabilities of seeding and harvest densities we characterize our MSC “True Age” in terms of their PDL.

How often should I feed your cells?

A: There is no need to feed cells between passages. Our media is engineered to be a batch culture media, where no media exchange or feed is necessary when following our suggested protocols.

Are your vials sold from pooled donors?

No, we do not pool donors at any time during our production. Master Cell Banks (MCBs) are created from each donor source. Working Cell Banks (WCBs) are produced from our MCBs for general product sales.

What characterization do you provide for your hMSCs?

We characterize our hMSCs by following ISCT criteria: cell identity (surface marker expression), functional potency (angiogenic cytokine and IDO secretion), and trilineage differentiation (adipo-, osteo-, and chondrogenesis). This information is provided to allow customers to choose the optimal hMSC tissue type and donor for their specific application or target indication.